Context. JDQ443 (Novartis Institute for Biomedical Research) is an oral KRAS^G12C^ inhibitor being developed for various advanced solid tumors . Despite accounting for 85% of RAS oncogenic mutations in all cancers, KRAS was considered undruggable until 2013 when a report describing the targetability of the KRAS^G12C^ mutant by small molecule [...]